Xenon Pharmaceuticals stock
XENENASDAQXenon Pharmaceuticals Inc., HealthcareISIN CA98420N1050
37Score 37 out of 100, Weak
Price and trend
47 / 100
Price history
+3.3% in one yearThe chart shows daily closes over 12 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 22% below it.
Since October 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Overheated: the price has risen very quickly lately (RSI 75).
The price is 42% below its 52-week high. Largest decline in 12 years: 90% (January 2015 to November 2017).
Chart figures for advanced users
- SMA 50$41.53
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$52.28
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)75
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$33.49
- The lowest closing price of the last twelve months.
- Resistance$70.96
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Xenon Pharmaceuticals Inc. belongs to the Biotechnology industry (Canada) and, with a market value of $4.03B, is number 85 of 296 companies in its industry on MEQIRI.
- For fiscal 2026, analysts expect on average revenue of $1.44M (down 80.8%) and adjusted earnings per share of −$4.58.
- MEQIRI Score 37 out of 100 (Weak): rank 607 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $548.89M, financial debt $7.94M.Stability 73
Weaknesses
- DilutionShare count up 129% since 2020.Capital allocation 18
- Loss-makingLoss of $345.91M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$279.92M over the last 12 months.Fundamentals 17
Its standout strength is stability, while fundamentals and profitability hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 35 to 37.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
From 2025 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 66%, operating −4974%, net −4612%. Last 12 months: net 0%. From 2025 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Debt & balance sheet
latest quarterDebt is low; no interest coverage is reported.
Earnings
- Next earnings
- 25 Feb 2027in 105 days
- Last reported
- 9 Nov 2026EPS reported −$1.11 (expected −$1.13)in line with expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$4.58+0.5%
- Revenue
- $1.44M+7.1%
- Earnings per share
- −$4.60+1.7%
- Revenue
- $27.81M+3.1%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −1.5%First Phase 3 results still expected in the first half of 2027, cash expected to fund operations into 2029.
“We continue to expect our first Phase 3 MDD study results in the first half of 2027, and we will narrow that guidance as we get closer to the top line readout.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 6 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
2 insiders bought on the open market in the last 6 months, $1.68M in total. 4 insiders sold, $1.2M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Xenon Pharmaceuticals
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 37
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- CRISPR TherapeuticsCRSP $4.44B37
- CamurusCAMX.ST $4.42B74
- Relay TherapeuticsRLAY $4.36B46
- Tango TherapeuticsTNGX $4.34B45
- Amylyx PharmaceuticalsAMLX $4.09B43
- AbCellera BiologicsABCL $3.9B38
- Tarsus PharmaceuticalsTARS $3.78B43
- Enliven TherapeuticsELVN $3.77B45
ETFs that hold Xenon Pharmaceuticals
Held by 16 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Harbor Health Care UCITS ETF AccW311 | 1.68% | 0.89% | €11.61M |
| iShares Healthcare Innovation UCITS ETF2B78 | 0.35% | 0.40% | €1.49B |
| iShares Ageing Population UCITS ETF2B77 | 0.33% | 0.40% | €807M |
Show 5 more
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.24% | 0.35% | €1.21B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.16% | 0.30% | €185.82M |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.13% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.13% | 0.30% | €2.17B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.11% | 0.43% | €2.48B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Nov 2015)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.